Twente Optical Perfusion Camera: whole field imaging of microcirculation in psoriasis and clinically unaffected skin.

Twente Optical Perfusion Camera: whole field imaging of microcirculation in psoriasis and clinically unaffected skin. - Microcirculation in psoriasis.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON37689

Enrollment

Registered

2012-03-15

Start date

2012-07-04

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients must meet the following criteria: • Adults older than 18 year of age • Patients with plaque psoriasis • Patients who are on Dovobet treatment (betamethasone dipropionate calcipotriol ointment) • Patients must be willing to discontinue their topical treatment of one plaque for 2 weeks and of one plaque for a maximum of 10 weeks • Patients must be willing to give a written informed consent • Patients must be able to adhere to the visit schedule

Exclusion criteria

Exclusion criteria: Patients will be wxcluded from this study shen any of the following criteria listed below are met: • Children or adolescents younger than 18 years of age • Patients with a history or signs of other inflammatory skin diseases, for example atopic dermatitis • Patients with relevant co-morbidities • Patients using varying doses of systemic antipsoriatic treatment like methotrexate or biologics. Doses have to be stable for at least 3 months.

Design outcomes

Primary

Measure	Time frame
The main study endpoints will be: (i) The visualization of vascular involvement in the pathogenesis of psoriasis with the TOPCam, preferably by showing the appearance of newly formed psoriatic plaques in the clinically uninvolved skin, predicted by change in the microcirculation. (ii) The detection of hot- and cold spots within a psoriatic lesion using the TOPCam, correlating them to immunohistochemical findings of inflammation and angiogenesis in both an untreated plaque and a plaque treated with Dovobet. (iii) The presence of inflammatory cells, like CD3 positive T-cells and polymorphonuclear leukocytes (PMNs) in the tissues with an increased microcirculation, obtained from patients with psoriasis.	—

Measure

Time frame

The main study endpoints will be: (i) The visualization of vascular involvement in the pathogenesis of psoriasis with the TOPCam, preferably by showing the appearance of newly formed psoriatic plaques in the clinically uninvolved skin, predicted by change in the microcirculation. (ii) The detection of hot- and cold spots within a psoriatic lesion using the TOPCam, correlating them to immunohistochemical findings of inflammation and angiogenesis in both an untreated plaque and a plaque treated with Dovobet. (iii) The presence of inflammatory cells, like CD3 positive T-cells and polymorphonuclear leukocytes (PMNs) in the tissues with an increased microcirculation, obtained from patients with psoriasis.

—

Secondary

Measure	Time frame
The secondary study endpoints will be: (i) The visualization of vascular and histological changes as an effect of Dovobet ointment. (ii) Applicability of the TOPCam in daily clinical practice.	—

Countries

Netherlands

Outcome results